

Principles of Immunopharmacology

Edited by Frans P. Nijkamp
and Michael J. Parnham

Birkhäuser Verlag
Basel • Boston • Berlin

Contents

| | |
|--|------|
| Preface to the first edition. | xv |
| Preface to the second edition. | xvi |
| Abbreviations. | xvii |
| A Mechanisms of immunity | |
| A.1 Hematopoiesis, including lymphocyte development and maturation | |
| Introduction: acquisition of specificity. | 3 |
| Hematopoiesis. | 3 |
| T and B lymphocytes: common origin from hematopoietic stem cells. | 6 |
| Specificity: rearrangement of genes encoding antigen receptors. | 7 |
| T lymphocyte maturation in the thymus. | 8 |
| B lymphocyte development in the bone marrow. | 11 |
| Mature T and B lymphocytes: tolerance. | 14 |
| T and B lymphocyte development and maturation: relevance for immunopharmacology. | 14 |
| Summary. | 15 |
| Selected readings. | 16 |
| Recommended Website. | 16 |
| References. | 16 |
| A.2 T cell-mediated immunity | |
| Introduction. | 19 |
| Biology of the T lymphocyte immune response. | 19 |
| Composition of the T cell network. | 20 |
| T cell subset markers. | 22 |
| Effectors of T cell-mediated immunity. | 23 |
| Mechanisms of T cell-mediated cytotoxicity. | 24 |
| Mechanisms of T cell activation. | 25 |
| Tolerance. | 26 |
| Summary. | 28 |
| Selected readings. | 28 |
| A.3 Antibody diversity and ES cell-mediated immunity | |
| Antibodies and immunoglobulins. | 29 |
| Structure of immunoglobulins. | 29 |
| The generation of antibody diversity. | 30 |
| B cell receptor and Signal transduction | 32 |
| B lymphocyte costimulation. | 34 |

| | | |
|------------|---|-----|
| | Cytokine regulation. | 36 |
| | T cell-independent B lymphocyte activation. | 36 |
| | Primary and secondary antibody response. | 37 |
| | Biological functions of antibodies. | 39 |
| | Clinical relevance and future prospects. | 41 |
| | Summary. | 43 |
| | Selected readings. | 43 |
| | Recommended Websites. | 43 |
| | References. | 44 |
| A.4 | Cytokines | |
| | Introduction. | 45 |
| | Differentiation factors. | 46 |
| | Activation and growth factors of lymphocytes. | 48 |
| | Mediators of inflammation. | 51 |
| | Regulatory factors of immune reactions. | 54 |
| | Chemokines. | 54 |
| | Inhibition of cytokines. | 58 |
| | Summary and outlook. | 60 |
| | Selected readings. | 60 |
| | Recommended website. | 60 |
| | References. | 60 |
| A.5 | Innate immunity - phagocytes, natural killer cells and the complement System | |
| | Phagocytes. | S3 |
| | Natural killer cells. | 72 |
| | The complement System. | 75 |
| | Summary. | 79 |
| | Selected readings. | 79 |
| | References. | 79 |
| A.6 | Inflammatory mediators and intracellular signalling | |
| | Introduction. | 81 |
| | Eicosanoids. | 81 |
| | Platelet-activating factor (PAF). | 87 |
| | Toll-like receptors. | 89 |
| | Cytokines. | 89 |
| | Chemokines and their [ntracellular signalling. | 92 |
| | Neuropeptides. | 93 |
| | Kinins. | 93 |
| | Nitric oxide. | 95 |
| | Reactive oxygen species. | 98 |
| | Amines. | 99 |
| | Summary. | 101 |
| | Selected readings. | 101 |
| | References. | 101 |
| A.7 | Immune response in human pathology: infections caused by bacteria, viruses, fungi, and parasites | |
| | Infections. | 105 |
| | Natural resistance. | 105 |

| | |
|---|-----|
| Specific resistance. | 107 |
| Defence against bacteria, viruses, fungi, and parasites. | 109 |
| Pathogenesis of shock. | 110 |
| Human immunodeficiency virus infection. | 112 |
| Vaccines and vaccination. | 113 |
| Infections in the new millennium. | 114 |
| Summary. | 115 |
| Acknowledgements. | 115 |
| Selected readings. | 115 |
| Recommended Websites. | 115 |
| A.8 Immune response in human pathology: hypersensitivity and autoimmunity | |
| Introduction. | 117 |
| Hypersensitivity. | 117 |
| Autoimmunity. | 123 |
| Conclusion. | 125 |
| Summary. | 126 |
| Selected readings. | 126 |
| Recommended website. | 126 |
| References. | 126 |
| A.9 Cancer immunity | |
| Introduction: cancer immunity from a historical perspective. | 129 |
| Key players in the immune responses against cancer. | 130 |
| Expression of targets for the immune System by cancer cells. | 132 |
| Immunotherapy of cancer. | 136 |
| Conclusions and future developments. | 140 |
| Summary. | 141 |
| Selected readings. | 141 |
| References. | 142 |
| A.10 Neuroimmunoendocrinology | |
| Historical background. | 149 |
| Regulation of the immune System by neuroendocrine hormones. | 150 |
| Neuroendocrine hormone release by immune System cells. | 153 |
| Functions of leukocyte-derived peptide hormones <i>in vivo</i> | 155 |
| Summary and conclusions. | 156 |
| Acknowledgements. | 157 |
| Selected readings. | 157 |
| Recommended Websites. | 157 |
| References. | 157 |
| B Immunodiagnosis | |
| B.1 Antibody detection | |
| Introduction. | 163 |
| Basic principle of immunoassays. | 163 |
| Antibody structure. | 164 |
| Clinical relevance of antibody detection. | 164 |

| | | |
|------------|---|-----|
| | Antibody detection methods. | 165 |
| | Summary. | 170 |
| | Selected readings. | 170 |
| | References. | 170 |
| B.2 | Immunoassays | |
| | Introduction. | 171 |
| | Basic principles of assay design. | 171 |
| | Components of immunoassays. | 173 |
| | Data presentation and curve plotting. | 175 |
| | Selected immunoassays. | 176 |
| | Assay Performance and validation. | 178 |
| | Summary. | 180 |
| | Selected readings. | 181 |
| | References. | 181 |
| B.3 | Flow cytometry | |
| | Introduction. | 183 |
| | Mechanistic principles. | 183 |
| | Classification/types of assay. | 185 |
| | Components/construction of assays. | 187 |
| | Examples and their application. | 192 |
| | Summary. | 195 |
| | Selected readings. | 195 |
| | References. | 195 |
| B.4 | Gene arrays | |
| | Introduction. | 197 |
| | Principle of the technology. | 197 |
| | Production of microarrays. | 201 |
| | Application of microarrays. | 203 |
| | Array data: acquisition, analysis and mining. | 205 |
| | Examples of microarray experiments. | 207 |
| | Summary. | 210 |
| | Selected readings. | 211 |
| | Recommended Websites. | 211 |
| | References. | 211 |
| B.5 | Proteomics and applications within the drug development pipeline | |
| | Introduction. | 213 |
| | Traditional proteomics. | 213 |
| | Array-based proteomics. | 222 |
| | Summary. | 225 |
| | Selected readings. | 226 |
| | Recommended Websites. | 226 |
| | References. | 226 |

C Immunotherapeutics

C.1 Vaccines

| | |
|---|-----|
| Introduction. | 231 |
| Historical background. | 231 |
| Current vaccine categories. | 232 |
| Pharmacological effects of vaccination. | 237 |
| New developments. | 239 |
| Summary. | 243 |
| Selected readings. | 244 |
| Recommended Websites. | 244 |
| References. | 244 |

C.2 Sera and immunoglobulins

| | |
|--|-----|
| Humoral immunity. | 247 |
| Antibody structure. | 247 |
| Effector functions of human Ig. | 249 |
| The catabolism of Ig. | 254 |
| Ig preparations for medical use. | 254 |
| Indications. | 256 |
| Dosage and administration. | 258 |
| Side-effects of Ig therapy. | 258 |
| Monoclonal Ab (mAb). | 260 |
| Summary. | 262 |
| Selected readings. | 262 |
| Recommended Websites. | 263 |
| References. | 263 |

C.3 Anti-allergic drugs

| | |
|--|-----|
| Introduction. | 265 |
| Disodium cromoglycate and nedocromil sodium (chromones). | 265 |
| Histamine receptor antagonists. | 270 |
| Anti-IgE. | 275 |
| Summary. | 277 |
| Selected readings. | 277 |
| References. | 278 |

C.4 Drugs for the treatment of asthma and COPD

| | |
|--|-----|
| Introduction. | 281 |
| Bronchodilators. | 281 |
| Controller drugs. | 300 |
| Mediator antagonists. | 309 |
| Steroid-sparing therapies. | 312 |
| New drugs for asthma and COPD. | 314 |
| Other drugs. | 328 |
| Summary. | 329 |
| Selected readings. | 330 |
| Recommended Websites. | 330 |
| References. | 330 |

| | | |
|------------|--|------------|
| C.5 | Immunostimulants in cancer therapy | |
| | Introduction. | 345 |
| | Recombinant proteins. | 345 |
| | Natural and synthetic BRMs. | 357 |
| | Combination immunotherapy and cellular therapy. | 363 |
| | Conclusion. | 365 |
| | Summary. | 366 |
| | Selected feadings. | 367 |
| | Recommended Websites. | 367 |
| | References. | 368 |
| C.6 | Anti-infective activity of immunomodulators | |
| | Introduction. | 377 |
| | Cytokine immunomodulators. | 378 |
| | Interferons and combinations. | 379 |
| | Colony-stimulating factors. | 381 |
| | Emerging cytokine therapies. | 381 |
| | Synthetic immunomodulators. | 383 |
| | Emerging therapies with synthetic immunomodulators. | 384 |
| | Microbial immunomodulators. | 386 |
| | Summary. | 388 |
| | Recommended Websites. | 388 |
| | References. | 389 |
| C.7 | Mild plant and dietary immunomodulators | |
| | Introduction. | 391 |
| | Plant immunostimulants. | 391 |
| | Zinc. | 394 |
| | Dietary antioxidants. | 396 |
| | Phenolic compounds as immunomodulators. | 400 |
| | Emerging therapies and siimmary. | 403 |
| | Selected readings. | 403 |
| | Recommended Websites. | 403 |
| | References. | 403 |
| C.8 | Influence of antibacterial drugs on the immune System | |
| | Introduction. | 407 |
| | Antibacterial agents (ABA) and the immune System. | 407 |
| | Class-specific immunomodulatory effects. | 409 |
| | Non-antibacterial effects of antibacterial agents. Therapeutic implications. | 426 |
| | Conclusions. | 430 |
| | Summary. | 430 |
| | Selected readings. | 432 |
| | Recommended Website. | 433 |
| | References. | 433 |
| C.9 | Immunosuppressives in transplant rejection | |
| | Introduction. | 441 |
| | Calcineurin inhibitors. | 446 |

| | |
|--|------------|
| Inhibitors of growth factor modulation. | 450 |
| Cytotoxic drugs. | 451 |
| Other immunosuppressive drugs. | 454 |
| Biologicals. | 455 |
| New approaches and perspectives. | 457 |
| Summary. | 460 |
| Selected readings. | 461 |
| References. | 461 |
| C.10 Cytotoxic drugs | |
| Background. | 465 |
| Azathioprine. | 465 |
| Cyclophosphamide. | 467 |
| Fludarabine. | 469 |
| Methotrexate. | 471 |
| Mycophenolic acid. | 474 |
| Conclusions. | 477 |
| Summary. | 477 |
| Selected readings. | 479 |
| References. | 479 |
| C.11 Corticosteroids | |
| Introduction. | 483 |
| Chemical structures. | 485 |
| Modes of action. | 485 |
| Pharmacological effects. | 487 |
| Pharmacokinetics. | 490 |
| Clinical indications. | 490 |
| Side-effects. | 492 |
| Summary. | 494 |
| Selected readings. | 494 |
| Recommended Websites. | 494 |
| References. | 494 |
| C.12 Non-steroidal anti-inflammatory drugs | |
| Introduction. | 499 |
| Mode of action of non-steroid anti-inflammatory drugs. | 499 |
| Cyclo-oxygenase-1 and cyclo-oxygenase-2. | 500 |
| Structural basis for COX-2 selectivity. | 503 |
| Additional uses for selective COX-2 inhibitors. | 504 |
| COX-2 inhibitors and cancers. | 504 |
| Premature labour. | 505 |
| Alzheimer's disease. | 506 |
| Other cyclo-oxygenases. | 506 |
| Summary. | 506 |
| Selected readings. | 507 |
| References. | 508 |

| | | |
|-------------|--|-----|
| C 13 | Disease-modifying anti-rheumatic drugs | |
| | Introduction | 511 |
| | Pathophysiology of rheumatoid arthritis | 511 |
| | Corticosteroids | 512 |
| | Disease-modifying anti-rheumatic drugs (DMARD) | 514 |
| | Methotrexate | 514 |
| | Antimalarials (chloroquine and hydroxychloroquine) | 520 |
| | Azathioprine | 521 |
| | Cyclosporin | 523 |
| | Gold complexes | 525 |
| | Leflunomide | 527 |
| | Penicillamine | 530 |
| | Sulfasalazine | 532 |
| | Tetracyclines (minocycline) | 533 |
| | Biological anti-rheumatic therapy | 535 |
| | Combination DMARD therapies | 536 |
| | Summary | 537 |
| | Selected readings | 539 |
| | References | 540 |
| C.14 | Perspectives of immunotherapy in the management of asthma and other allergic conditions | |
| | Introduction | 545 |
| | General aspects of immunotherapy in allergy and asthma | 545 |
| | Non-specific immunomodulatory therapies | 546 |
| | Specific mediator antagonists | 546 |
| | Anti-cytokine therapy | 547 |
| | Cytokine therapy | 547 |
| | Specific immunotherapy | 548 |
| | Mechanisms of immunotherapy | 548 |
| | SIT for asthma | 549 |
| | Comparison of SIT with other types of treatment for asthma | 549 |
| | Effects on natural history of allergic disease | 549 |
| | Future directions | 550 |
| | Conclusions | 551 |
| | Summary | 552 |
| | Selected readings | 552 |
| | References | 552 |
| D | Immunotoxicology | |
| D.1 | Immunotoxicology | |
| | Introduction | 559 |
| | Mechanisms of immunotoxicity by pharmaceuticals | 560 |
| | Procedures for preclinical testing of direct immunotoxicity | 570 |
| | Procedures for preclinical testing of sensitizing capacity | 574 |
| | Procedures for immunotoxicity testing in humans | 577 |
| | Immunotoxicity regulations | 579 |
| | Conclusions | 584 |
| | Summary | 585 |
| | Selected readings | 585 |
| | References | 585 |

Appendices

| | |
|---------------------------------|-----|
| Appendix C.1. | 593 |
| Appendix C.3. | 598 |
| Appendix C.5. | 602 |
| Appendix C.6. | 605 |
| Appendix C.7. | 606 |
| Appendix C.8. | 610 |
| Appendix C.12/1. | 611 |
| Appendix C.12/2. | 618 |
| Appendix C.13. | 623 |
| Appendix D.1. | 625 |
| Glossary. | 627 |
| List of contributors. | 645 |
| Index. | 651 |